EverHint – Dip Bounce V2 (Reclaim) – Top 10 Signals for Nov 10, 2026
Excerpt: 10 signals (from 17 total). Healthcare leads (3). price range $17-$168.
What This Signal Is
Production-ready dip-bounce strategy using reclaim pattern with Phase 2 market regime filters. Improved win rate from 40.42% (V1) to 50.18% (V2) with VIX and record high filters.
Entry Criteria:
- Minimum dip: 3.3% (open to intraday low)
- Minimum bounce: 1.0% from low
- Net change range: -2.0% to +0.3%
- Price above SMA(200)
- Minimum ADV: $40M
Holding period: 1-5 days | Risk level: Medium
Market Context
Equity markets are showing modest broad-based weakness on November 10, 2026, with the Nasdaq leading declines at -0.74% while the S&P 500 and Dow Jones post shallower pullbacks. This mild risk-off tone creates a nuanced environment for dip-bounce reclaim strategies — the selling pressure is measured rather than panicked, which historically supports cleaner technical setups where price dips into support and reclaims key levels without the erratic chop that accompanies sharper selloffs.
The VIX at 19.53, while declining nearly 2% on the day, sits in a zone that reflects moderate uncertainty rather than complacency or fear. This level of implied volatility is generally constructive for intraday swing signals — wide enough to generate meaningful price movement and profit potential, yet not so elevated that false breakouts and whipsaws dominate. For dip-bounce setups specifically, a VIX in the high teens tends to produce more reliable reclaim patterns as institutional participants remain engaged rather than sidelined.
Healthcare's emergence as the top sector generating signals is notable given the broader market's mild risk-off posture. Defensive sectors like healthcare often attract rotation when growth and tech face headwinds, as evidenced by the Nasdaq's relative underperformance today. This rotation dynamic may be amplifying dip-bounce setups within the sector, as capital inflows provide underlying support that helps price levels hold and reclaim technical thresholds — a key ingredient for this strategy type to perform well.
📊 Signals (10 of 17 total)
Ranked by dip magnitude (highest first)
| # | Ticker | Company | Sector | Price | Score | MCap |
|---|---|---|---|---|---|---|
| 1 | WRBY | Warby Parker Inc. | Consumer Cyclical | $29.90 | 0.36 | $3.3B |
| 2 | ETON | Eton Pharmaceuticals, ... | Healthcare | $67.54 | 0.23 | $1.9B |
| 3 | MGNI | Magnite, Inc. | Communication Services | $28.52 | 0.20 | $4.1B |
| 4 | GEO | The GEO Group, Inc. | Industrials | $31.94 | 0.18 | $4.2B |
| 5 | TIGO | Millicom International... | Communication Services | $88.75 | 0.16 | $14.9B |
| 6 | ZETA | Zeta Global Holdings C... | Technology | $35.07 | 0.16 | $8.8B |
| 7 | PRGO | Perrigo Company plc | Healthcare | $16.83 | 0.16 | $2.3B |
| 8 | SENEA | Seneca Foods Corporation | Consumer Defensive | $168.21 | 0.15 | $1.1B |
| 9 | CXW | CoreCivic, Inc. | Industrials | $31.59 | 0.14 | $3.1B |
| 10 | VIRT | Virtu Financial, Inc. | Financial Services | $57.75 | 0.13 | $5.1B |
Recent Headlines
ETON (Eton Pharmaceuticals, Inc.)
- Eton Pharmaceuticals stock hits all-time high at 66.54 USD
MGNI (Magnite, Inc.)
- Gracenote and Magnite Bring Greater Content Intelligence to CTV Curation
- Trade Desk Falls 7% Despite Earnings Beat as Overnight Rally Fades; PubMatic Drops 5%, Magnite Holds Steady
TIGO (Millicom International Cellular S.A.)
- TIGO ENERGY DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Tigo Energy, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - TYGO
- Buy, Sell, or Hold? Tuesday’s Top Upgrades and Downgrades: Cloudflare, Deckers Outdoors, DraftKings, MongoDB, Nike, Oneok, Philip Morris International, Riot Platforms, Wix.com, and More
ZETA (Zeta Global Holdings Corp.)
- Zeta Global Stock Surges on Positive Q3 Results
- ZETA Q3 Earnings Call Highlights AI Growth and Higher Outlook
- Zeta Global: Strong Q3 Revenue Growth And A Bullish Guide, Hiking My Target
Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.
This is not financial advice. Market conditions change rapidly.
Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/
📢 Support the project by liking, sharing, or subscribing — it helps more readers discover these signals.